Tove Henriksen

2.4k total citations
42 papers, 1.0k citations indexed

About

Tove Henriksen is a scholar working on Neurology, Cognitive Neuroscience and Cellular and Molecular Neuroscience. According to data from OpenAlex, Tove Henriksen has authored 42 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Neurology, 11 papers in Cognitive Neuroscience and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Tove Henriksen's work include Parkinson's Disease Mechanisms and Treatments (33 papers), Neurological disorders and treatments (26 papers) and Botulinum Toxin and Related Neurological Disorders (12 papers). Tove Henriksen is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (33 papers), Neurological disorders and treatments (26 papers) and Botulinum Toxin and Related Neurological Disorders (12 papers). Tove Henriksen collaborates with scholars based in Denmark, United Kingdom and Sweden. Tove Henriksen's co-authors include К. Ray Chaudhuri, Per Odin, Regina Katzenschlager, Angelo Antonini, Olivier Rascol, Werner Poewe, Harry Staines, Teus van Laar, Andrew J. Lees and Claudia Trenkwalder and has published in prestigious journals such as Brain, The Lancet Neurology and Journal of Cerebral Blood Flow & Metabolism.

In The Last Decade

Tove Henriksen

39 papers receiving 987 citations

Peers

Countries citing papers authored by Tove Henriksen

Since Specialization

Citations

This map shows the geographic impact of Tove Henriksen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tove Henriksen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tove Henriksen more than expected).

Fields of papers citing papers by Tove Henriksen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tove Henriksen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tove Henriksen. The network helps show where Tove Henriksen may publish in the future.

Co-authorship network of co-authors of Tove Henriksen

This figure shows the co-authorship network connecting the top 25 collaborators of Tove Henriksen. A scholar is included among the top collaborators of Tove Henriksen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tove Henriksen. Tove Henriksen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment patterns with long-term foslevodopa/foscarbidopa use in Parkinson’s disease 2025 ·Parkinsonism & Related Disorders ·Jason Aldred, Tove Henriksen, Martin Bouchard, Juan Carlos Martínez‐Castrillo, Michael J. Soileau, David G. Standaert, Lars Bergmann, Resmi Gupta, Pavnit Kukreja, Rashed Shah, Stuart Isaacson	1
2	Cholinergic patterns correlate with dopamine medication ON freezing of gait in Parkinson's disease 2025 ·Brain ·(unknown), (unknown), Erik Johnsen, Mette Møller, Erik Hvid Danielsen, Tove Henriksen, Andreas Nørgaard Glud, Yen Tai, (unknown), Ann Kristin Knudsen, Kaare Meier, Jacob Horsager, Niels Okkels, Jens Christian Hedemann Sørensen, Per Borghammer, Elena Moro, Nicola Pavese	0
3	Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease 2025 ·Movement Disorders Clinical Practice ·Jason Aldred, Manon Bouchard, Juan Carlos Martínez‐Castrillo, Michael J. Soileau, Amy M. Spiegel, Lars Bergmann, Resmi Gupta, (unknown), Pavnit Kukreja, David G. Standaert, Stuart Isaacson, Tove Henriksen	0
4	Efficacy and safety of foslevodopa/foscarbidopa continuous subcutaneous infusion administered as monotherapy in patients with Parkinson’s disease 2024 ·Parkinsonism & Related Disorders ·Jason Aldred, Tove Henriksen, Martin Bouchard, Juan Carlos Martínez‐Castrillo, Michael J. Soileau, Allen M. Spiegel, Lars Bergmann, Resmi Gupta, Pavnit Kukreja, David G. Standaert	1
5	Grasping the big picture: impact analysis of screening tools for timely referral for device-aided therapies 2024 ·Journal of Neural Transmission ·(unknown), Haidar S. Dafsari, Wolfgang H. Jost, Norbert Kovács, Zvezdan Pirtošek, Tove Henriksen, Cristian Falup‐Pecurariu, Michal Minár, Erik Buskens, Teus van Laar	1
6	Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review 2023 ·Journal of Neural Transmission ·(unknown), Tove Henriksen, Jarosław Sławek, Onanong Phokaewvarangkul, Erik Buskens, Teus van Laar	14
7	Infusion Therapies in the Treatment of Parkinson’s Disease 2023 ·Journal of Parkinson s Disease ·Teus van Laar, К. Ray Chaudhuri, Angelo Antonini, Tove Henriksen, Maja Trošt	17
8	Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience 2023 ·Journal of Neural Transmission ·Tove Henriksen, Regina Katzenschlager, Roongroj Bhidayasiri, Harry Staines, (unknown), Andrew J. Lees	12
9	Spinal cord stimulation therapy for patients with Parkinson’s disease and gait problems (STEP-PD): study protocol for an exploratory, double-blind, randomised, placebo-controlled feasibility trial 2022 ·BMJ Neurology Open ·(unknown), (unknown), Erik Johnsen, Mette Møller, Erik Hvid Danielsen, Tove Henriksen, Andreas Nørgaard Glud, Yen Tai, (unknown), Kaare Meier, Per Borghammer, Elena Moro, Jens Christian Hedemann Sørensen, Nicola Pavese	4
10	Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries 2022 ·Neurology and Therapy ·Angelo Antonini, Rajesh Pahwa, Per Odin, Tove Henriksen, Michael J. Soileau, (unknown), Stuart Isaacson, Aristide Merola, (unknown), Josefa Domingos, Ali Alobaidi, Yash J. Jalundhwala, (unknown), Juan Carlos Parra, Pavnit Kukreja, Koray Onuk, Lars Bergmann, James Pike, К. Ray Chaudhuri	10
11	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study 2021 ·Parkinsonism & Related Disorders ·Regina Katzenschlager, Werner Poewe, Olivier Rascol, Claudia Trenkwalder, Günther Deuschl, К. Ray Chaudhuri, Tove Henriksen, Teus van Laar, (unknown), Harry Staines, Andrew J. Lees	46
12	Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey 2020 ·Journal of Neural Transmission ·(unknown), Alexandra Rizos, Anna Sauerbier, Cristian Falup‐Pecurariu, Per Odin, Angelo Antonini, Pablo Martínez‐Martín, B. Kessel, Tove Henriksen, Monty Silverdale, (unknown), К. Ray Chaudhuri	7
13	Everyday Occupations and Other Factors in Relation to Mental Well-Being among Persons with Advanced Parkinson’s Disease 2019 ·Occupational Therapy In Health Care ·(unknown), (unknown), (unknown), Tove Henriksen, Dag Nyholm, Per Odin, Mona Eklund	5
14	Interdisciplinary recognizing and managing of drug‐induced tardive oromandibular dystonia: two case reports 2018 ·Clinical Case Reports ·Merete Bakke, Tove Henriksen, (unknown), (unknown), Eigild Møller	6
15	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial 2018 ·The Lancet Neurology ·Regina Katzenschlager, Werner Poewe, Olivier Rascol, Claudia Trenkwalder, Günther Deuschl, К. Ray Chaudhuri, Tove Henriksen, Teus van Laar, (unknown), Senthil Vel, Harry Staines, Andrew J. Lees	201
16	Practical management of adverse events related to apomorphine therapy 2016 ·Parkinsonism & Related Disorders ·Roongroj Bhidayasiri, Pedro Ruiz, Tove Henriksen	31
17	Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therapy 2016 ·Parkinsonism & Related Disorders ·Roongroj Bhidayasiri, (unknown), Onanong Jitkritsadakul, Susan Calne, Tove Henriksen, (unknown), (unknown), (unknown), (unknown), Jirada Sringean, Teus van Laar, (unknown), К. Ray Chaudhuri	28
18	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program 2015 ·Parkinsonism & Related Disorders ·Per Odin, К. Ray Chaudhuri, John T. Slevin, Jens Volkmann, Erik Sveberg Dietrichs, Pablo Martínez‐Martín, Joachim K. Krauss, Tove Henriksen, Regina Katzenschlager, Angelo Antonini, Olivier Rascol, Werner Poewe	151
19	Dependency and transfer incomes in idiopathic Parkinson's disease. 2014 ·PubMed ·(unknown), (unknown), Tove Henriksen, Christina Funch Lassen	3
20	Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect 2011 ·Journal of Parkinson s Disease ·Pablo Martínez‐Martín, Prashanth Reddy, Angelo Antonini, Tove Henriksen, Regina Katzenschlager, Per Odin, Antonia Todorova, Y. Naidu, S. Tluk, (unknown), Anne Martin, К. Ray Chaudhuri	94

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact